胰高血糖素样肽-1受体激动剂的停用 - Suppr

Suppr

超能文献

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

作者信息

Khan Sadiya S, Ndumele Chiadi E, Kazi Dhruv S

机构信息

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

出版信息

JAMA. 2025 Jan 14;333(2):113-114. doi: 10.1001/jama.2024.22284.

DOI:10.1001/jama.2024.22284

PMID:39535741

Abstract

摘要

相似文献

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

JAMA. 2025 Jan 14;333(2):113-114. doi: 10.1001/jama.2024.22284.

Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).

Diabetes Ther. 2021 Jan;12(1):345-361. doi: 10.1007/s13300-020-00977-w. Epub 2020 Dec 9.

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.

Patient Prefer Adherence. 2020 Nov 27;14:2337-2345. doi: 10.2147/PPA.S277676. eCollection 2020.

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK.

BMJ Open Diabetes Res Care. 2022 Jan;10(1). doi: 10.1136/bmjdrc-2021-002517.

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349.

Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.

Diabetes Obes Metab. 2022 May;24(5):788-805. doi: 10.1111/dom.14640. Epub 2022 Jan 21.

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.

Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.

Future Cardiol. 2023 Feb;19(2):105-115. doi: 10.2217/fca-2022-0093. Epub 2023 Mar 28.

Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.

Acta Neuropsychiatr. 2025 Feb 14;37:e50. doi: 10.1017/neu.2025.4.

Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.

Diabetes Ther. 2022 Mar;13(3):389-421. doi: 10.1007/s13300-021-01198-5. Epub 2022 Feb 17.

引用本文的文献

Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.

Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382.

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.

Obes Pillars. 2025 Jun 3;15:100181. doi: 10.1016/j.obpill.2025.100181. eCollection 2025 Sep.

Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.

Obesity (Silver Spring). 2025 Jun 10. doi: 10.1002/oby.24331.

Titration and discontinuation of semaglutide for weight management in commercially insured US adults.

Obesity (Silver Spring). 2025 Jul;33(7):1243-1248. doi: 10.1002/oby.24315. Epub 2025 Jun 4.

Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.

Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.

Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.

Am J Lifestyle Med. 2025 May 30:15598276251344827. doi: 10.1177/15598276251344827.

Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.

Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336.

Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke.

Curr Neurol Neurosci Rep. 2025 May 21;25(1):36. doi: 10.1007/s11910-025-01423-9.

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验